multiple-sclerosis

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 43/100

   Advances in neurological therapies: A review of clinical trials in Alzheimer's, Parkinson's, and multiple sclerosis

   ✓ Peer-reviewed alzhub usefulness score 43 out of 100. The American journal of medicine · 2025-11-27 · Treatments

   The period from 2020 to 2025 marked a pivotal juncture in the treatment of major neurological diseases, with Phase II-IV trials delivering the first compelling evidence for disease-modifying interventions in Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

   • Treatments
   • Clinical Trials
   • Side Effects
2. 48/100

   Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions

   ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Expert opinion on investigational drugs · 2025-11-10 · Drug development

   Moreover, signals of reduced neurological impairment and lower dementia incidence in broader diabetic cohorts further support their translational promise.

   • Treatments
   • Brain Biology
3. 41/100

   Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer's Disease and Multiple Sclerosis

   ✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024-07-17 · TREM2 and immune genetics

   Human genetics and preclinical studies have identified key contributions of TREM2 to several neurodegenerative conditions, inspiring efforts to modulate TREM2 therapeutically.

   • Genetics
   • Early Stage
   • Brain Biology

All topic tags with their study counts